Last reviewed · How we verify
medical cannabis
medical cannabis is a Small molecule drug developed by HaEmek Medical Center, Israel. It is currently in Phase 3 development for Chronic pain, Nausea and vomiting associated with chemotherapy, Muscle spasms. Also known as: medical marijuana, medicinal cannabinoids (MCBD), CBD/THC, Cannabis oil containing 10% delta-9-tetrahydrocannabinol (THC) and 5% cannabidiol (CBD).
Medical cannabis exerts its effects through the body's endocannabinoid system, influencing various physiological processes.
Medical cannabis has been studied as a potential treatment for various conditions, including chemotherapy-induced peripheral neuropathy, osteoarthritis knee, cannabis use disorder, and attention deficit hyperactivity disorder (ADHD), according to ClinicalTrials.gov. The exact mechanism of medical cannabis is unknown, as indicated by ChEMBL, but it has been used as a prescribed treatment for patients by physicians, as described on Wikipedia.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | medical cannabis |
|---|---|
| Also known as | medical marijuana, medicinal cannabinoids (MCBD), CBD/THC, Cannabis oil containing 10% delta-9-tetrahydrocannabinol (THC) and 5% cannabidiol (CBD) |
| Sponsor | HaEmek Medical Center, Israel |
| Target | CB1 and CB2 receptors |
| Modality | Small molecule |
| Therapeutic area | Pain management, Nausea and vomiting, Muscle spasms |
| Phase | Phase 3 |
Mechanism of action
The endocannabinoid system is a complex network of receptors and chemicals that play a crucial role in regulating functions such as pain, mood, and memory. Medical cannabis interacts with this system, producing therapeutic effects in conditions like chronic pain, nausea, and muscle spasms.
Approved indications
- Chronic pain
- Nausea and vomiting associated with chemotherapy
- Muscle spasms
Common side effects
- Dry mouth
- Dizziness
- Fatigue
Key clinical trials
- Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF
- Exploring The Effect Of Cannabidiol On Cannabis Tolerance Using A Novel Vaporiser Device In Heavy Users (Stage 1) (NA)
- Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain (NA)
- Medical Cannabis During Chemoradiation for Head and Neck Cancer
- Community Based Cannabis Cessation Program
- Medical Phenotyping of NHS General Adult Psychiatry (GAP) Inpatients
- Medical Cannabis for Nausea in Patients Receiving Moderately or Highly Emetogenic Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- medical cannabis CI brief — competitive landscape report
- medical cannabis updates RSS · CI watch RSS
- HaEmek Medical Center, Israel portfolio CI
Frequently asked questions about medical cannabis
What is medical cannabis?
How does medical cannabis work?
What is medical cannabis used for?
Who makes medical cannabis?
Is medical cannabis also known as anything else?
What development phase is medical cannabis in?
What are the side effects of medical cannabis?
What does medical cannabis target?
Related
- Target: All drugs targeting CB1 and CB2 receptors
- Manufacturer: HaEmek Medical Center, Israel — full pipeline
- Therapeutic area: All drugs in Pain management, Nausea and vomiting, Muscle spasms
- Indication: Drugs for Chronic pain
- Indication: Drugs for Nausea and vomiting associated with chemotherapy
- Indication: Drugs for Muscle spasms
- Also known as: medical marijuana, medicinal cannabinoids (MCBD), CBD/THC, Cannabis oil containing 10% delta-9-tetrahydrocannabinol (THC) and 5% cannabidiol (CBD)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing